Middle East Pharmaceutical Industries Co (SAU:4016) Piotroski F-Score: 4 (As of Sep. 04, 2026) — 33% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SAU:4016 Middle East Pharmaceutical Industries Co SAU:4016
21 GF Score
Price ﷼66.85
! 3 Warning Signs
View Full Analysis

What is Middle East Pharmaceutical Industries Co Piotroski F-Score?

Middle East Pharmaceutical Industries Co SAU:4016 -1.62% 21 Piotroski F-Score is 4 as of Sep. 04, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates SAU:4016 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 986 Drug Manufacturers companies, Middle East Pharmaceutical Industries Co ranks worse than 60.95% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Middle East Pharmaceutical Industries Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Middle East Pharmaceutical Industries Co's Piotroski F-Score or its related term are showing as below:

SAU:4016' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 7
Current: 4

During the past 3 years, the highest Piotroski F-Score of Middle East Pharmaceutical Industries Co was 7. The lowest was 4. And the median was 6.

Middle East Pharmaceutical Industries Co  (SAU:4016) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Middle East Pharmaceutical Industries Co Piotroski F-Score Related Terms


Middle East Pharmaceutical Industries Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Middle East Pharmaceutical Industries Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Middle East Pharmaceutical Industries Co Piotroski F-Score Chart

Middle East Pharmaceutical Industries Co Annual Data
Trend Dec23 Dec24 Dec25
Piotroski F-Score
N/A N/A 7.00

Middle East Pharmaceutical Industries Co Quarterly Data
Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A 7.00 N/A 4.00

SAU:4016 vs ZTS, UTHR, VTRS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Middle East Pharmaceutical Industries Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Middle East Pharmaceutical Industries Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Middle East Pharmaceutical Industries Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Middle East Pharmaceutical Industries Co's Piotroski F-Score falls into.


SAU:4016
21GF Score
Middle East Pharmaceutical Industries Co SAU:4016
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was 8.278 + 44.522 + 26.899 + 28.802 = ﷼108.5 Mil.
Cash Flow from Operations was 24.796 + 10.5 + 11.332 + 22.674 = ﷼69.3 Mil.
Revenue was 107.95 + 137.518 + 130.127 + 136.485 = ﷼512.1 Mil.
Gross Profit was 62.474 + 90.465 + 80.617 + 85.495 = ﷼319.1 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(561.11 + 565.608 + 599.53 + 626.478 + 689.411) / 5 = ﷼608.4274 Mil.
Total Assets at the begining of this year (Jun25) was ﷼561.1 Mil.
Long-Term Debt & Capital Lease Obligation was ﷼33.1 Mil.
Total Current Assets was ﷼479.5 Mil.
Total Current Liabilities was ﷼177.7 Mil.
Net Income was 3.867 + 44.807 + 19.398 + 24.811 = ﷼92.9 Mil.

Revenue was 81.061 + 135.988 + 97.361 + 117.656 = ﷼432.1 Mil.
Gross Profit was 45.701 + 89.082 + 60.267 + 73.632 = ﷼268.7 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(465.958 + 494.042 + 526.781 + 548.335 + 561.11) / 5 = ﷼519.2452 Mil.
Total Assets at the begining of last year (Jun24) was ﷼466.0 Mil.
Long-Term Debt & Capital Lease Obligation was ﷼14.1 Mil.
Total Current Assets was ﷼379.3 Mil.
Total Current Liabilities was ﷼133.8 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Middle East Pharmaceutical Industries Co's current Net Income (TTM) was 108.5. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Middle East Pharmaceutical Industries Co's current Cash Flow from Operations (TTM) was 69.3. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=108.501/561.11
=0.1933685

ROA (Last Year)=Net Income/Total Assets (Jun24)
=92.883/465.958
=0.19933771

Middle East Pharmaceutical Industries Co's return on assets of this year was 0.1933685. Middle East Pharmaceutical Industries Co's return on assets of last year was 0.19933771. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Middle East Pharmaceutical Industries Co's current Net Income (TTM) was 108.5. Middle East Pharmaceutical Industries Co's current Cash Flow from Operations (TTM) was 69.3. ==> 69.3 <= 108.5 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=33.148/608.4274
=0.05448144

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=14.079/519.2452
=0.02711436

Middle East Pharmaceutical Industries Co's gearing of this year was 0.05448144. Middle East Pharmaceutical Industries Co's gearing of last year was 0.02711436. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=479.495/177.723
=2.69799069

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=379.262/133.822
=2.8340781

Middle East Pharmaceutical Industries Co's current ratio of this year was 2.69799069. Middle East Pharmaceutical Industries Co's current ratio of last year was 2.8340781. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Middle East Pharmaceutical Industries Co's number of shares in issue this year was 35. Middle East Pharmaceutical Industries Co's number of shares in issue last year was 35. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=319.051/512.08
=0.62304913

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=268.682/432.066
=0.62185407

Middle East Pharmaceutical Industries Co's gross margin of this year was 0.62304913. Middle East Pharmaceutical Industries Co's gross margin of last year was 0.62185407. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=512.08/561.11
=0.91261963

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=432.066/465.958
=0.92726383

Middle East Pharmaceutical Industries Co's asset turnover of this year was 0.91261963. Middle East Pharmaceutical Industries Co's asset turnover of last year was 0.92726383. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+0+0+1+1+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Middle East Pharmaceutical Industries Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Middle East Pharmaceutical Industries Co (SAU:4016) has a Piotroski F-Score of 4 as of Sep. 04, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Middle East Pharmaceutical Industries Co and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Middle East Pharmaceutical Industries Co's Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, Middle East Pharmaceutical Industries Co ranks #601 out of 986 companies in the Drug Manufacturers industry, placing it in the top 61%.
Is Middle East Pharmaceutical Industries Co's Piotroski F-Score too high?
Middle East Pharmaceutical Industries Co's current Piotroski F-Score of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Middle East Pharmaceutical Industries Co's value of 4 is 20% below this industry median. Based on the distribution chart, Middle East Pharmaceutical Industries Co ranks #601 out of 986 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Middle East Pharmaceutical Industries Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Middle East Pharmaceutical Industries Co's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Middle East Pharmaceutical Industries Co ranks #601 out of 986 companies for Piotroski F-Score. This places Middle East Pharmaceutical Industries Co in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Middle East Pharmaceutical Industries Co's value of 4 is 20% below this benchmark. Historically, Middle East Pharmaceutical Industries Co's own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Middle East Pharmaceutical Industries Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 986 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Middle East Pharmaceutical Industries Co's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Middle East Pharmaceutical Industries Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Middle East Pharmaceutical Industries Co's current Piotroski F-Score is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Middle East Pharmaceutical Industries Co stock overvalued right now?
Middle East Pharmaceutical Industries Co (SAU:4016) has a current Piotroski F-Score of 4. The current Piotroski F-Score is 4, which is 33% below median its 10-year median of 6.00 and 20% below the Drug Manufacturers industry median of 5.00. Middle East Pharmaceutical Industries Co's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Middle East Pharmaceutical Industries Co (SAU:4016), the current Piotroski F-Score is 4 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Middle East Pharmaceutical Industries Co Business Description

Address 8146 King Muhammad V, Sulaimaniyah, P.O. Box 4180, Riyadh, SAU, 11491
Middle East Pharmaceutical Industries Co is a holding company engaged in manufacturing medicines, medicated and non-medicated creams and gels. The company operates in Private, Public, and Export segments. Geographically, it generates the majority of its revenue from Saudi Arabia.
21GF Score

Get the complete analysis for SAU:4016

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

﷼66.85
Price